Chairman of the Syndicate of Iranian Pharmaceutical Industries: We will Witness CPhI Iran Starting from Next Year

Dr. Abbas Kebriaeizade stated that: "With attention to the good response of domestic and international companies to the Second International Iran Pharma Exhibition, this will be this exhibition's last version and from next year onward, we will be witnessing CPhI Iran.

In the first seminar of the elites in the country's pharmaceutical system, revolving around the subject of opportunities and challenges facing Iran's pharmaceutical industry in incorporating the World Trade Organization, he added: "Currently, 97 percent of pharmaceutical need is provided through domestic production, which in itself, shows Iran's self-sufficiency in this domain. This economic and confident approach is derived from Imam Khomeini's ideology and is now applied in the pharmaceutical industry."

Chairman of the Syndicate of Iranian Pharmaceutical Industries stated that: "Iran's pharmaceutical industry is now able to manufacture all forms of pharmaceuticals; with all these efforts, Iran has the broadest distribution chain in the country and the most expansive drug network in comparison with similar countries. The existence of more than 10 thousand pharmacies and drugstores and the broad network of pharmaceuticals procurement indicates self-sufficiency in the pharmaceuticals sector. Accordingly, before the finalization our incorporation into the World Trade Organization, we must know what consequences and impacts does the incorporation into the WTO has in policies, production, distribution and supplying."

The first seminar of the elites in the country's pharmaceutical system, revolving around the subject of analyzing opportunities and challenges facing Iran's pharmaceutical industry in incorporating in the World Trade Organization was held on May 10th 2016, in Parvin Etesami Hall, at Shahid Beheshti University, with Dr. Rasool Dinarvand, Deputy of the Minister of Health and chairman of the Food and Drug Administration, together with a number of CEOs from Iran's pharmaceutical companies.